CNO Financial Group, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $CNO in the last 30 days.
See all $CNO insider activity →CNO Financial Group (CNO) disclosed that officer Karen DeToro plans to sell 9,336 shares of CNO common stock, valued at $511,002.96 as of September 1, 2026. The planned sales include 1,836 restricted shares and 7,500 shares from a stock option exercise. DeToro also reported a prior sale of 9,374 shares on August 31, 2026 for $515,366.21.
CNO Financial Group reports 18% CAGR growth in worksite sales since 2020, driven by agent productivity and expansion. Medicare Supplement sales also rising, with strong persistency and market share potential. Growth supported by exclusive distribution and high-touch service, according to the company.
California Nanotechnologies (TSXV:CNO) reported Q1 FY2027 revenue of $917,854, up 28% from $716,553 a year earlier, for the quarter ended May 31, 2026. Adjusted EBITDA loss narrowed to $129,031 from $152,707, while net loss was $449,598. The company attributes growth to customer diversification and a nuclear supply-chain pivot tied to initial SMR component purchase orders.
Over the past 7 days, alphai's AI scored 2 news stories mentioning CNO (CNO Financial Group, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent CNO coverage spans earnings, financial news and corporate actions.
The insider sale adds modest supply to the market but is unlikely to move the stock materially.
Positive growth trend may support bullish sentiment but lacks concrete new catalyst.
Near-term trading focus is whether the nuclear pivot converts into follow-on, recurring SMR component orders and improves profitability trajectory.
Guidance raise and margin/earnings drivers suggest improved earnings power, but liquidity at the holding company fell and life NAP declined.
Guidance raise plus improving expense ratio supports a constructive near-term earnings outlook, but leverage risk remains a counterweight.
alphai scores every news story that mentions CNO with an AI model for sentiment and relevance, and aggregates insider trades from CNO Financial Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
CNO Financial Group (CNO) disclosed that officer Karen DeToro plans to sell 9,336 shares of CNO common stock, valued at $511,002.96 as of September 1, 2026. The planned sales include 1,836 restricted shares and 7,500 shares from a stock option exercise. DeToro also reported a prior sale of 9,374 shares on August 31, 2026 for $515,366.21.
1 min readCNO Financial Group reports 18% CAGR growth in worksite sales since 2020, driven by agent productivity and expansion. Medicare Supplement sales also rising, with strong persistency and market share potential. Growth supported by exclusive distribution and high-touch service, according to the company.
1 min readCalifornia Nanotechnologies (TSXV:CNO) reported Q1 FY2027 revenue of $917,854, up 28% from $716,553 a year earlier, for the quarter ended May 31, 2026. Adjusted EBITDA loss narrowed to $129,031 from $152,707, while net loss was $449,598. The company attributes growth to customer diversification and a nuclear supply-chain pivot tied to initial SMR component purchase orders.
6 min readCNO Financial Group (NYSE:CNO) reported Q2 2026 operating EPS of $1.26, up 45% year over year, and net operating income of $119.5 million. Total new annualized premiums rose 7% to a record. Full-year EPS guidance was raised to $4.60 to $4.80. The company also repurchased $60 million of shares.
6 min readZacks reports CNO Financial Group (CNO) has gained 28.6% year to date, citing growth in annuity, life and health premiums. The article says 2026 consensus earnings are $4.74/share on about $4.0B revenue, with beats in four straight quarters and 23.2% average surprise. It also notes raised 2026 operating EPS guidance to $4.60-$4.80 and Q2 repurchases of $60M plus $16.8M dividends.
6 min readCNO Financial Group (NYSE: CNO) reported higher Q2 2026 profit and EPS, according to the company. The update indicates improved earnings performance for the quarter, which may affect investor expectations for the insurer’s near-term results.
1 min readCNO Financial Group (NYSE:CNO) said its board declared a quarterly cash dividend of $0.18 per common share. The dividend is payable Sept. 24, 2026, to shareholders of record as of Sept. 10, 2026, according to the company. It noted this would be its 58th consecutive quarterly dividend.
2 min readSimply Wall St reports that CNO Financial Group raised its full-year 2026 operating EPS guidance by 8% at the midpoint, citing stronger fundamentals, improving profitability, and repeatable results. The update is linked to expectations for margin expansion and capital efficiency, alongside recent share repurchases. The article also cites forecasts of $4.4B revenue and $483.3M earnings by 2029.
4 min readCNO Financial Group (CNO) reported Q2 call highlights. Life NAP in the Consumer Division fell 9% on weaker direct-to-consumer sales, while annuity collected premiums hit a record $536 million (+3%) and annuity account values rose 7%. Brokerage and advisory assets rose 24% to record, totaling over $19B (+11%). Net investment income rose 8% with a 6.16% new-money rate. CNO returned $77M to shareholders, including $60M in buybacks, and expects 2026 operating ROE above its prior 12% target.
6 min readCNO Financial Group reported Q2 2026 sales growth for a 16th consecutive quarter. Insurance policy income rose to $680.7 million from $651.3 million a year earlier, and net income increased to $125.9 million, or $1.33 per diluted share, from $91.8 million, or $0.91. CNO raised full-year 2026 operating EPS guidance by 8% at the midpoint and estimated RBC at 377% as of June 30.
5 min read
